PepSee goes public — a new software tool for therapeutic peptide analysis & design

webinar

Thu, 25 Jan 2018, 16:00 CET (Berlin)

Dr. Marcus Gastreich, BioSolveIT GmbH, St. Augustin, Germany

PepSee goes public — a new software tool for therapeutic peptide analysis & design

In collaboration with Zealand Pharma, a leading and experienced therapeutic peptide specialist in Copenhagen, we conceived a tool with the major focus of having it rolled-out and operational ASAP, targeting the most relevant problems and most ugly time-eaters first thus boosting the efficiency of the organization. After approx. 2 years, we can now roll out the tool in its current status to the general public, and academics can use it for free.

PepSee sports, amongst others:

  • visual pattern recognition support for SAR work
  • versatile colorings, for ex. by mutation differences to a reference peptide
  • a plethora of sorting and filtering facilities
  • FASTA, PLN, and TXT import
  • XLS export
  • on-the-fly alignment including manual intervention
  • interfaces to predictive methods such as fibrillation highlighting, and allows validation and registration of new sequences
  • A first PDF text mining function pulling peptides from patents et al.

Current news

What's So Special About The 'Activity Spotter'? Detailed Insights Into SeeSAR's New Mode
April 29, 2026 10:22 CEST
SeeSAR’s Activity Spotter Mode is designed to dismantle the barrier of raw data and actionable SAR. It helps to answer the most relevant fields in hit-to-lead and lead optimization campaigns: 3D SAR and pharmacophore modeling. Which structural features in my molecule set are associated with activity? Which ones are linked...
Read on
Tool of the Month - FlexX
April 29, 2026 08:53 CEST
Spring is Molecular Docking Season The bread and butter of computational chemistry: predicting potential binding modes, which serves as a crucial foundation for SAR analysis and design decisions, is being made available to everyone this month with the proprietary docking tool FlexX. Validated by over 10,000 citations of its original...
Read on
The 95 Billion Update: Access the REAL Space
April 9, 2026 13:57 CEST
The latest update of Enamine’s REAL Space brings a new expansion, now featuring over 94.5 billion accessible, drug-like products, approaching the 100 billion mark. Built from 173 curated reaction protocols and 202,620 in-stock reagents and building blocks based on Enamine’s in-house knowledge, this version further enhances the world’s largest commercially...
Read on